ALPS Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

ALPS Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-123,896	Closed	-$2.2M	–	992
2018 Q3	$2.2M	Buy	123,896 +24,136	+24%	+$414K	0.01%	239
2018 Q2	$1.38M	Buy	+99,760	New	+$1.18M	0.01%	279
2016 Q2	–	Sell	-47,207	Closed	-$146K	–	652
2016 Q1	$146K	Sell	47,207 -8,089	-15%	-$26.4K	﹤0.01%	612
2015 Q4	$222K	Sell	55,296 -10,334	-16%	-$47.6K	﹤0.01%	671
2015 Q3	$301K	Buy	65,630 +24,039	+58%	+$126K	﹤0.01%	651
2015 Q2	$216K	Buy	41,591 +20,839	+100%	+$125K	﹤0.01%	676
2015 Q1	$130K	Sell	20,752 -44,910	-68%	-$259K	﹤0.01%	649
2014 Q4	$413K	Sell	65,662 -7,438	-10%	-$45.3K	﹤0.01%	528
2014 Q3	$444K	Buy	+73,100	New	+$499K	﹤0.01%	579

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

ALPS Advisors's ECYT Position: Q4 2018 in Review

ALPS Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 123,896 shares — an estimated $2.2M sold.

ALPS Advisors first reported a position in ECYT in Q3 2014 and held it in 9 quarters. The position peaked at $2.2M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

ALPS Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
ALPS Advisors sold 123,896 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $2.2M.
ALPS Advisors first reported a position in Endocyte, Inc. Common Stock in Q3 2014 and held it in 9 quarters.
ALPS Advisors's Endocyte, Inc. Common Stock position peaked at $2.2M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on ALPS Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.